Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.

Simple item page
dc.contributor.authorGuedes, Paulo Marcos da Matta
dc.contributor.authorUrbina, Julio Alberto
dc.contributor.authorLana, Marta de
dc.contributor.authorAfonso, Luís Carlos Crocco
dc.contributor.authorVeloso, Vanja Maria
dc.contributor.authorTafuri, Washington Luiz
dc.contributor.authorCoelho, George Luiz Lins Machado
dc.contributor.authorChiari, Egler
dc.contributor.authorBahia, Maria Terezinha
dc.date.accessioned2017-03-29T16:48:48Z
dc.date.available2017-03-29T16:48:48Z
dc.date.issued2004
dc.description.abstractAlbaconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity and a remarkably long half-life in dogs, monkeys, and humans. In the present work, we investigated the in vivo activity of this compound against two strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas’ disease, using dogs as hosts. The T. cruzi strains used in the study were previously characterized (murine model) as susceptible (strain Berenice-78) and partially resistant (strain Y) to the drugs currently in clinical use, nifurtimox and benznidazole. Our results demonstrated that albaconazole is very effective in suppressing the proliferation of the parasite and preventing the death of infected animals. Furthermore, the parasitological, PCR, serological, and proliferative assay results indicated parasitological cure indices of 25 and 100% among animals inoculated with T. cruzi strain Y when they were treated with albaconazole at 1.5 mg/kg of body weight/day for 60 and 90 days, respectively. On the other hand, although albaconazole given at 1.5 mg/kg/day was very effective in suppressing the proliferation of the parasite in animals infected with the Berenice-78 T. cruzi strain, no parasitological cure was observed among them, even when a longer treatment period (150 doses) was used. In conclusion, our results demonstrate that albaconazole has trypanocidal activity in vivo and is capable of inducing radical parasitological cure, although natural resistance to this compound was also indicated. Furthermore, the compound can be used in long-term treatment schemes (60 to 150 days) with minimal toxicity and thus represents a potentially useful candidate for the treatment of human Chagas’ disease.pt_BR
dc.identifier.citationGUEDES, P. M. da M. et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrobial Agents and Chemotherapy, v. 48, p. 4286-4292, 2004. Disponível em: <http://aac.asm.org/content/48/11/4286.long>. Acesso em: 20 jan. 2017.pt_BR
dc.identifier.doihttps://doi.org/10.1128/AAC.48.11.4286-4292.2004
dc.identifier.issn1098-6596
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/7484
dc.identifier.uri2http://aac.asm.org/content/48/11/4286.longpt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.titleActivity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Collections
DEFAR - Artigos publicados em periódicos